

17 Vaccines

in the clinical stages of development



Discover & Deliver: Update on the Global Search for a Coronavirus Vaccine

As coronavirus cases increased in at least [35 U.S. states](#) and the global number of cases surpassed 10 million, the question at the front of everyone's minds is: When will a vaccine be ready?

Scientists, industry, and the academic community are moving at unprecedented speed to identify a viable vaccine candidate, and progress is being made every day.

There are currently [17 vaccine candidates](#) in the clinical stages of development, with another 132



under preclinical evaluation. So who leads the way?

The University of Oxford and AstraZeneca are currently conducting a Phase III trial to test the efficacy of their novel coronavirus candidate. As the number of cases in the UK decreased, the University of Oxford recently embarked on clinical trials in [South Africa and Brazil](#) to test the vaccine's efficacy in countries where people have a higher risk of exposure to the coronavirus. They are also set to begin a large-scale Phase III trial in the U.S., following a [\\$1.2 billion commitment](#) by the U.S. government to invest in the vaccine as a part of Operation Warp Speed.

The innovative biotech company, Moderna, is close on the heels of the University of Oxford in the race to develop a vaccine. Moderna, which [received widespread media coverage](#) following the release of Phase I data in May, will begin Phase III trials for its COVID-19 candidate in 30,000 participants in July. Just last week, [Moderna announced](#) a partnership with Catalent to prepare an initial 100 million doses of the vaccine, which could be distributed as early as October, should the vaccine receive FDA approval.

Governments, the biopharmaceutical industry, and the academic community recognize that a vaccine can't come soon enough. The unparalleled level of public-private collaboration will help ensure that at least one – if not multiple – coronavirus vaccines should soon be available, which will place the global community on the path to a return to work, health, and the new normal of life in a COVID-19 world.

—Jonathan Weinberger, Executive Vice President, Global Innovation Policy Center